Table 4.

Clinical Outcomes Following Initial Therapy for Each American Joint Cancer Committee Stage

	n = 588
Clinical outcome following initial therapy	AJCC I (n = 281)	AJCC II (n = 71)	AJCC III (n = 89)	AJCC IV (n = 147)
No evidence of disease	66%	48%	63%	20%
(n = 305)	(186)	(34)	(56)	(29)
Persistent disease, biochemical evidence only	23%	18%	21%	10%
(n = 108)	(64)	(12)	(18)	(14)
Persistent disease, structurally identifiable	10%	34%	14%	68%
(n = 167)	(28)	(25)	(13)	(101)
Recurrent disease	1%	0%	2%	2%
(n = 8)	(3)	(0)	(2)	(3)